Harnessing the Power of Microbiota and Metabolites to Treat Cancer

Methods and composition for treating cancer.
Tech ID #: 1379.1
IP status: national phase applications covering North America, Australia, China, and South Korea.
Immune checkpoint blockade therapy promoting intestinal bacteria.
Pre-clinical data showing significantly enhanced efficacy of immune checkpoint inhibitors in mouse models of cancer.
Seeking licensing partnerships.

BACKGROUND 

The current invention relates to a method for the treatment of cancer using an immune checkpoint inhibitor (ICI) in combination with one or more bacteria selected from Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species.

The inventors have isolated and cultured tumor-associated bacteria species from homogenized tumor tissue. They have identified three bacterial species that showed efficacy in enhancing the potency of ICIs in treating colorectal cancer (CRC). Without ICIs, those bacteria alone do not have effects on CRC. The inventors also identified inosine as the key microbial metabolite that mediates the immune-enhancing properties of bacteria. Inosine can be used in combination therapy with ICIs to treat CRC. The ICI-potentiating effect of bacteria is CRC-subtype specific.

 

AREAS OF APPLICATION 

  • Treatment of cancer
    • Cancer immunotherapy
    • Bacterial-immune checkpoint blockade co-therapy

 

COMPETITIVE ADVANTAGES

  • Potential to lead to novel cancer therapeutics.
  • Validated bacterial growth and isolation protocols.

 

PUBLICATIONS AND RESOURCES

Announcements

Events
02 Oct 2023

Social Innovator Breakfast Club – October 2

News

UCalgary’s new Aerospace Innovation Hub soars to new heights with $2.5 million funding

News

Light might be the answer to our data security issues, quantum researcher says

Questions? Need more information?

Reach out and connect. Our tech transfer team is ready to help.

Contact Us